Trial · NCT07905885
Cycling During Dialysis: A Feasibility and Safety Study
NCT07905885, Not applicable, Not yet recruiting, Sunnybrook Health Sciences Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cycling During Dialysis: A Feasibility and Safety Study. Trials, record NCT07905885. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905885
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cycling During Dialysis: A Feasibility and Safety Study
- NCT number
- NCT07905885
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Conditions
- Hemodialysis, Kidney Disease, End-Stage, Fatigue
- Interventions
- Supervised Intradialytic Cycling
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment rate | Recruitment period (up to 3 months, approximately October to December 2026) | Number of eligible patients who consent to take part, reported as the number enrolled per month and as the percentage of eligible patients approached who enroll. |
| Primary | Adherence to the cycling program | 12 weeks (during the 3-month intervention) | Percentage of scheduled supervised cycling sessions that each participant completes, based on the Nursing Monitoring Form and Exercise Prescription Log. |
| Primary | Retention | 12 weeks | Percentage of enrolled participants who complete the 3-month intervention and the end-of-study assessments. |
| Primary | Number and type of adverse events during cycling sessions | Every cycling session over 12 weeks | Adverse events recorded by nurses on the Adverse Event Report Form, including symptomatic hypotension, chest pain, tachycardia, low oxygen saturation, severe cramping, and vascular access problems such as needle dislodgement, plus sessions stopped early for safety criteria. |
| Secondary | Change in fatigue (Fatigue Severity Scale) | Baseline and 12 weeks | Change in the 9-item Fatigue Severity Scale score. Higher scores mean more fatigue. |
| Secondary | Change in quality of life (KDQOL-SF) | Baseline and 12 weeks | Change in Kidney Disease Quality of Life Short Form scores. Higher scores mean better quality of life. |
| Secondary | Change in walking distance (6-Minute Walk Test) | Baseline and 12 weeks | Change in distance walked in 6 minutes, in metres, measured by the physiotherapist. |
| Secondary | Change in dialysis adequacy (Kt/V) | Baseline, week 6, and 12 weeks | Change in Kt/V from routine monthly blood work. |
| Secondary | Participant satisfaction | Final week of the study (about 12 weeks) | Participant Satisfaction Questionnaire ratings of ease, safety, fit with dialysis, and willingness to recommend. |
| Other | Nurse satisfaction and perceived feasibility | End of study (about 12 weeks) | Nurse Satisfaction Questionnaire on equipment setup and calibration, training, supervision confidence, workload, and challenges and opportunities for routine care. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905885
GET https://conductscience.org/api/trials/v1/NCT07905885/registered